IBD: Phase II trial success for anti-MADCAM1 antibody

  • I. R. Dickson
  • Published 2017 in Nature Reviews Gastroenterology &Hepatology


Many patients with ulcerative colitis are refractory towards conventional therapies, highlighting a need for treatments with novel mechanisms of action. Promising targets include cell adhesion molecules such as MADCAM1 that mediate the migration of lymphocytes into sites of inflammation in the gut. In a phase II, randomized, placebo-controlled trial, the… (More)
DOI: 10.1038/nrgastro.2017.82


  • Presentations referencing similar topics